SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The antibiotic pipeline: reviving research and development and speeding drugs to market
7 references·0 citing·19 second hop
The antibiotic pipeline: reviving research and development and speeding drugs to market (2017)The antibiotic pipeline: reviving researc…21st Century Cures Act (2017)21st Century Cures ActPast, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications (2016)Past, Present, and Future of …The FDA Reboot of Antibiotic Development (2013)The FDA Reboot of Antibiotic …A comprehensive regulatory framework to address the unmet need for new antibacterial treatments (2013)A comprehensive regulatory fr…Fix the antibiotics pipeline (2011)Fix the antibiotics pipelineAntibacterial drug discovery: is it all downhill from here? (2004)Antibacterial drug discovery:…Why is big Pharma getting out of antibacterial drug discovery? (2003)Why is big Pharma getting out…New drug development in the United States from 1963 to 1999 (2001)Risks in new drug development: Approval success rates for investigational drugs (2001)The antibacterial drugs market (2006)Joining Forces to Prevent the Antibiotic Resistance Doomsday Scenario: The Rise of International Multisectoral Partnerships as a New Governance Model (2020)When Is Measuring Sensitivity and Specificity Sufficient To Evaluate a Diagnostic Test, and When Do We Need Randomized Trials? (2006)Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs (2010)The value of single-pathogen antibacterial agents (2013)Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach (2016)Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation (2017)History of Infections Associated With Combat-Related Injuries (2008)National trends in prescription drug expenditures and projections for 2017 (2017)An Analysis of Antibacterial Drug Development Trends in the United States, 1980–2019 (2020)Encouraging the Development of New Antibiotics: Are Financial Incentives the Right Way Forward? A Systematic Review and Case Study (2021)A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics (2015)Exploring different approaches to improve the success of drug discovery and development projects: a review (2020)Why big pharma has abandoned antibiotics (2020)Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind? (2018)An analysis of the strategic plan development processes of major public organisations funding health research in nine high-income countries worldwide (2020)How well can we assess the validity of non-randomised studies of medications? A systematic review of assessment tools (2021)
this work references cited by second hop

References

  • 2003Why is big Pharma getting out of antibacterial drug discovery?503 cited
  • 2011Fix the antibiotics pipeline474 cited
  • 2016Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications346 cited
  • 2004Antibacterial drug discovery: is it all downhill from here?169 cited
  • 201721st Century Cures Act164 cited
  • 2013The FDA Reboot of Antibiotic Development136 cited
  • 2013A comprehensive regulatory framework to address the unmet need for new antibacterial treatments120 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work